Research Article| Volume 38, ISSUE 7, P1750-1758, July 2016

Download started.


Impact of Antimicrobial Stewardship on Outcomes in Hospitalized Veterans With Pneumonia



      The purpose of this study was to evaluate the impact of an antimicrobial stewardship program (ASP) on outcomes for inpatients with pneumonia, including length of stay, treatment duration, and 30-day readmission rates.


      A retrospective chart review comparing outcomes of veterans admitted with pneumonia before (2005–2006) and after (2013–2014) implementation of an ASP was conducted; pneumonia was defined according to International Classification of Diseases, Ninth Revision (ICD-9) codes. Infectious diseases physicians and pharmacist in the ASP provided appropriate recommendations to the primary medicine teams. Bivariate analysis of baseline characteristics and comorbid conditions were performed between the time frames. Least squares regression was used to analyze length of stay, time of IV to PO conversions, and duration of antibiotics. Multivariate logistic regressions were used to determine odds of 30-day readmission and odds of Clostridium difficile infections between time periods.


      There were 86 patients in the pre-ASP period and 88 patients in the ASP period. Mean length of stay decreased from 8.1 to 6.6 days (P = 0.02), total duration of antibiotic therapy decreased from 12 to 8.5 days (P < 0.0001), and time of IV to PO antibiotic conversions decreased from 5.3 to 3.9 days (P = 0.0003), before ASP and during ASP, respectively. The odds ratio of 30-day readmission before ASP was 2.78 and 0.36 during the ASP (P = 0.05). The odds ratios of Clostridium difficile infections before ASP was 2.08 and 0.48 during the ASP (P = 0.37).


      The ASP interventions were associated with shorter durations of therapy, shorter lengths of stay, and lower rates of readmission and Clostridium difficile infections within 30 days. Limitations of this study are retrospective cohort design, small study population, limited study population diversity, and non-concurrent cohort times periods.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kochanek K.D.
        • Murphy S.L.
        • Xu J.
        • et al.
        Mortality in the United States, 2013.
        NCHS Data Brief. 2014; 178: 1-8
        • Murphy S.L.
        • Xu J.
        • Kochanek K.D.
        Deaths: final data for 2010.
        Natl Vital Stat Rep. 2013; 61: 1-117
        • Feikin D.R.
        • Schuchat A.
        • Kolczak M.
        • et al.
        Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997.
        Am J Public Health. 2000; 90: 223-229
        • Butler J.C.
        • Hofmann J.
        • Cetron M.S.
        • et al.
        The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention׳s Pneumococcal Sentinel Surveillance System.
        J Infect Dis. 1996; 174: 986-993
        • Nuorti J.P.
        • Butler J.C.
        • Crutcher J.M.
        • et al.
        An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents.
        N Engl J Med. 1998; 338: 1861-1868
        • Low D.E.
        What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by Streptococcus pneumoniae? (should macrolide monotherapy be used for mild pneumonia?).
        Infect Dis Clin North Am. 2013; 27: 87-97
        • Perez-Trallero E.
        • Marimon J.M.
        • Iglesias L.
        • et al.
        Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates.
        Emerg Infect Dis. 2003; 9: 1159-1162
        • Sanchez G.V.
        • Master R.N.
        • Karlowsky J.A.
        • et al.
        In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010.
        Antimicrob Agents Chemother. 2012; 56: 2181-2183
        • Vasoo S.
        • Barreto J.N.
        • Tosh P.K.
        Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician.
        Mayo Clin Proc. 2015; 90: 395-403
        • Aliberti S.
        • Di Pasquale M.
        • Zanaboni A.M.
        • et al.
        Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia.
        Clin Infect Dis. 2012; 54: 470-478
        • Gonzales R.
        • Bartlett J.G.
        • Besser R.E.
        • et al.
        Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods.
        Ann Emerg Med. 2001; 37: 690-697
        • Gonzales R.
        • Malone D.C.
        • Maselli J.H.
        • et al.
        Excessive antibiotic use for acute respiratory infections in the United States.
        Clin Infect Dis. 2001; 33: 757-762
        • Arias C.A.
        • Murray B.E.
        Antibiotic-resistant bugs in the 21st century--a clinical super-challenge.
        N Engl J Med. 2009; 360: 439-443
        • Hicks L.A.
        • Chien Y.-W.
        • Taylor T.H.
        • et al.
        Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003.
        Clin Infect Dis. 2011; 53: 631-639
        • Davidson R.
        • Cavalcanti R.
        • Brunton J.L.
        • et al.
        Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
        N Engl J Med. 2002; 346: 747-750
        • Hirsch E.B.
        • Tam V.H.
        Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes.
        Expert Rev Pharmacoecon Outcomes Res. 2010; 10: 441-451
        • Aloush V.
        • Navon-Venezia S.
        • Seigman-Igra Y.
        • et al.
        Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.
        Antimicrob Agents Chemother. 2006; 50: 43-48
        • Dellit T.H.
        • Owens R.C.
        • McGowan Jr., J.E.
        • et al.
        Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.
        Clin Infect Dis. 2007; 44: 159-177
        • Barlam T.F.
        • Cosgrove S.E.
        • Abbo L.M.
        • et al.
        Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.
        Clin Infect Dis. 2016; 62: e51-e77
        • Kaki R.
        • Elligsen M.
        • Walker S.
        • et al.
        Impact of antimicrobial stewardship in critical care: a systematic review.
        J Antimicrob Chemother. 2011; 66: 1223-1230
        • Vettese N.
        • Hendershot J.
        • Irvine M.
        • et al.
        Outcomes associated with a thrice-weekly antimicrobial stewardship programme in a 253-bed community hospital.
        J Clin Pharm Ther. 2013; 38: 401-404
        • Avdic E.
        • Cushinotto L.A.
        • Hughes A.H.
        • et al.
        Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia.
        Clin Infect Dis. 2012; 54: 1581-1587
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • et al.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Jeong B.H.
        • Koh W.J.
        • Yoo H.
        • et al.
        Performances of prognostic scoring systems in patients with healthcare-associated pneumonia.
        Clin Infect Dis. 2013; 56: 625-632
        • Fang W.F.
        • Yang K.Y.
        • Wu C.L.
        • et al.
        Application and comparison of scoring indices to predict outcomes in patients with healthcare-associated pneumonia.
        Crit Care. 2011; 15: R32
        • American Thoracic Society, Infectious Diseases Society of America
        Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.
        Am J Respir Crit Care Med. 2005; 171: 388-416
        • Cyriac J.M.
        • James E.
        Switch over from intravenous to oral therapy: A concise overview.
        J Pharmacol Pharmacother. 2014; 5: 83-87
        • Yu K.
        • Rho J.
        • Morcos M.
        • et al.
        Evaluation of dedicated infectious diseases pharmacists on antimicrobial stewardship teams.
        Am J Health Syst Pharm. 2014; 71: 1019-1028
        • Athanassa Z.
        • Makris G.
        • Dimopoulos G.
        • et al.
        Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis.
        Drugs. 2008; 68: 2469-2481
        • Kyne L.
        • Hamel M.B.
        • Polavaram R.
        • et al.
        Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile.
        Clin Infect Dis. 2002; 34: 346-353
        • Nowak M.A.
        • Nelson R.E.
        • Breidenbach J.L.
        • et al.
        Clinical and economic outcomes of a prospective antimicrobial stewardship program.
        Am J Health Syst Pharm. 2012; 69: 1500-1508
        • Lew K.Y.
        • Ng T.M.
        • Tan M.
        • et al.
        Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting.
        J Antimicrob Chemother. 2015; 70: 1219-1225
        • Dubberke E.R.
        • Burnham C.A.
        Diagnosis of Clostridium difficile Infection: Treat the Patient, Not the Test.
        JAMA Intern Med. 2015; 175: 1801-1802